The VANQUISH program consists of two trials evaluating VK2735: one in adults with obesity (VANQUISH-1), and one in adults with obesity and type 2 diabetes (VANQUISH-2)
They were developed on the basis of either human GLP-1 or exendin-4, a 39-amino acid peptide isolated from the Gila monster ( Heloderma suspectum ) venom, which shares 53% homology with GLP-1 [38]
Long-Term Outcomes: Will It Grow Back
For patients managing hypothyroidism while pursuing weight loss, understanding how these medications interactand how your individual genetic makeup influences GLP-1 responsecan help support more personalized treatment planning with your healthcare team
These degraders have generated significant scientific excitement but come with drawbacks
Eventually, she became so uncomfortable in her body that she took to wearing baggy sweatshirts, and tried to avoid mirrors and windows at the shopping mall